Inovio Pharmaceuticals Inc Share Price Nyse
Equities
INO
US45773H2013
Biotechnology & Medical Research
Sales 2024 * | 4L 3.47Cr | Sales 2025 * | 1.98Cr 164.63Cr | Capitalization | 29Cr 2.37TCr |
---|---|---|---|---|---|
Net income 2024 * | -12Cr -997.63Cr | Net income 2025 * | -10Cr -831.36Cr | EV / Sales 2024 * | 682 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 14.4 x |
P/E ratio 2024 * |
-2.55
x | P/E ratio 2025 * |
-3.64
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.4% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 25/19/25 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 01/02/01 |
Chief Tech/Sci/R&D Officer | - | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 01/03/01 |
Lota Zoth
BRD | Director/Board Member | 64 | 01/18/01 |
Jay Shepard
BRD | Director/Board Member | 66 | 15/20/15 |
1st Jan change | Capi. | |
---|---|---|
+54.05% | 6.39TCr | |
-2.02% | 4.18TCr | |
+40.01% | 4.05TCr | |
-10.22% | 2.72TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.87TCr | |
+2.89% | 1.27TCr | |
+22.40% | 1.21TCr | |
+27.49% | 1.21TCr |